Mylan N.V., MYL is in the exchange NASDAQ and its industry is Drugs – Generic in the sector of Healthcare. Based in USA, Mylan N.V., MYL has a market cap of 22097.13. Since its IPO date on the 12/18/1987, Mylan N.V., MYL performance year to date is -23.60%. Today Mylan N.V., MYL has gained 0.32%, with a current price of 41.31.
Ownership of the company is 0.50% for insider ownership while institutional ownership is 64.50%. The management of the company have seen the company have a payout ratio of 0.00%. Return of assets are at 3.40%, with return on investment at 8.20%.
In terms of debt levels and profit levels, Mylan N.V., MYL is seeing a long-term debt/equity of 1.24. While Total debt/equity is 1.31. With a profit margin of 8.10%, this is combined with a gross margin of 45.30%, and operating margin of 15.70%. Mylan N.V. ability to meet debt levels, with a current ratio of 3.2, while the quick ratio is 2.6.
For the last year Mylan N.V., MYL has seen a EPS growth of -31.50%. A performance for the year of 1.10%. The 52-week high is -25.58%, and the 52-week low is 9.90%. The average volume for Mylan N.V., MYL is 5546900.
With a target price of 56.56, can Mylan N.V., MYL reach this target? Looking at the value indicators of Mylan N.V., MYL. Mylan N.V. has a P/E of 26.26 and a forward P/E of 7.17. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.01. Mylan N.V. also has a P/S and a P/B of 2.22 and 2.02 respectively. For P/cash, Mylan N.V. has a value of 3.47, while it is 12.54 for P/free cash flow.
At the current price of 41.31, Mylan N.V. has a dividend yield of *TBA. We see a return on equity of 8.00%.
Looking more long-term Mylan N.V., is projected to get an EPS growth for the next five years of 13.08%. In the short-term an EPS growth of 16.20% in the next year is forecasted. This is after a EPS growth of -31.50% for this year and for the last five years a 20.20% growth has been seen.